An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
← catalyst calendarNCT06627335 · readout in 361 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
5,621estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-27 | actual | When the study began enrolling |
| Primary completion | 2027-08-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pregnancy Related
- Atopic Dermatitis
Interventions
- Drug: Ruxolitinib Cream — also filed as Opzelura
- Drug: TCS
Primary outcome
what the primary-completion date above is the date OFNumber of major congenital malformation (MCM)s
measured Up to 12 months after birth
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed